Stem cells represent an attractive resource for cardiac regeneration. However, the survival
and function of transplanted stem cells is poor and remains a major challenge for the …

Despite the dramatic improvements in the management of patients with chronic heart failure
which have occurred over the last decades, some of them still exhaust conventional drug …

Patients with chronic heart failure (HF) have a poor prognosis due to irreversible impairment
of left ventricular function, with 5-year survival rates< 60%. Despite advances in …

Stem/progenitor cells have been widely evaluated as a promising therapeutic option for
heart failure (HF). Numerous clinical trials with stem/progenitor cell-based therapy (SCT) for …

Mesenchymal stromal cells (MSCs) are promising cell therapy candidates, but their debated
efficacy in clinical trials still limits successful adoption. Here, we discuss proceedings from a …

Background Bone marrow (BM) transplantation is a life-saving therapy for hematological
diseases, and the BM harbors also highly useful (progenitor) cell types for novel cell …

Abstract Background Mesenchymal stem cells (MSCs) have emerged as living biodrugs for
myocardial repair and regeneration. Recent randomized controlled trials (RCTs) have …

Despite the improvements in the treatment of coronary artery disease (CAD) and acute
myocardial infarction (MI) over the past 20 years, ischemic heart disease (IHD) continues to …

Mesenchymal stem cell (MSC) therapy is a frequently used treatment option for achieving a
better prognosis in patients with heart failure (HF). However, due to reported adverse effects …

In this issue of the Journal of the American College of Cardiology, Perin et al 1 report the
results of the multinational, randomized, double-blinded, sham-controlled phase 3 DREAM …